These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33370202)

  • 1. Response by Flint et al to Letter Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment".
    Flint AC; Avins AL; Nguyen-Huynh MN
    Stroke; 2021 Jan; 52(1):e39-e40. PubMed ID: 33370202
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter by Katsanos and Tsivgoulis Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment".
    Katsanos AH; Tsivgoulis G
    Stroke; 2021 Jan; 52(1):e35-e36. PubMed ID: 33370177
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter by Tan and Xu Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment".
    Tan ZF; Xu AD
    Stroke; 2021 Jan; 52(1):e37-e38. PubMed ID: 33370181
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment.
    Flint AC; Avins AL; Eaton A; Uong S; Cullen SP; Hsu DP; Edwards NJ; Reddy PA; Klingman JG; Rao VA; Chan SL; Hartman J; Zrelak PA; Nguyen-Huynh MN
    Stroke; 2020 Sep; 51(9):2697-2704. PubMed ID: 32757749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.
    Lapchak PA; Araujo DM; Song D; Wei J; Zivin JA
    Stroke; 2002 May; 33(5):1411-5. PubMed ID: 11988623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator.
    Lapchak PA; Zivin JA
    Stroke; 2003 Aug; 34(8):2013-8. PubMed ID: 12855833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preprocedure Intravenous Recombinant Tissue Plasminogen Activator and Risk of Distal Embolization with Thrombectomy in Acute Ischemic Stroke.
    Qureshi AI; Asif A; Aytac E; Liaqat J; Gurkas E; Lobanova I; Saeed O; Ahsan H; Siddiq F; Gomez CR; French BR
    J Stroke Cerebrovasc Dis; 2019 Dec; 28(12):104362. PubMed ID: 31562039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute Thrombocytopenia After Tissue Plasminogen Activator for Stroke.
    Morena J; May C; Strohm T
    J Stroke Cerebrovasc Dis; 2020 Jul; 29(7):104865. PubMed ID: 32404288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
    Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
    Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter by Chao et al regarding article, "standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses".
    Chao AC; Po HL; Chan L
    Stroke; 2014 Dec; 45(12):e303. PubMed ID: 25342029
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter by Behrouz et Al regarding article, "Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion".
    Behrouz R; Mutgi SA; Silver B
    Stroke; 2015 Jun; 46(6):e149. PubMed ID: 25899241
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
    Adeoye O; Sucharew H; Khoury J; Tomsick T; Khatri P; Palesch Y; Schmit PA; Pancioli AM; Broderick JP;
    Stroke; 2015 Feb; 46(2):461-4. PubMed ID: 25523054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender Differences in Exclusion Criteria for Recombinant Tissue-Type Plasminogen Activator.
    Fredwall M; Sternberg S; Blackhurst D; Lee A; Leacock R; Nathaniel TI
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2569-2574. PubMed ID: 27618196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Study of Adverse Events After Intravenous Tissue-Type Plasminogen Activator Treatment of Acute Ischemic Stroke.
    Fernandez-Gotico H; Lightfoot T; Meighan M
    J Neurosci Nurs; 2017 Feb; 49(1):31-36. PubMed ID: 28060219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
    Simão F; Ustunkaya T; Clermont AC; Feener EP
    Blood; 2017 Apr; 129(16):2280-2290. PubMed ID: 28130211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemi orolingual angioedema after tPA administration for acute ischemic stroke.
    Madden B; Chebl RB
    West J Emerg Med; 2015 Jan; 16(1):175-7. PubMed ID: 25671036
    [No Abstract]   [Full Text] [Related]  

  • 17. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.
    Lapchak PA; Chapman DF; Zivin JA
    Stroke; 2000 Dec; 31(12):3034-40. PubMed ID: 11108768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
    Jin R; Xiao AY; Liu S; Wang M; Li G
    Stroke; 2018 Jul; 49(7):1708-1718. PubMed ID: 29844028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial.
    Adeoye O; Sucharew H; Khoury J; Vagal A; Schmit PA; Ewing I; Levine SR; Demel S; Eckerle B; Katz B; Kleindorfer D; Stettler B; Woo D; Khatri P; Broderick JP; Pancioli AM
    Stroke; 2015 Sep; 46(9):2529-33. PubMed ID: 26243231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.